"Reszinate—A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratro" by Henry Kaplan, Kai Wang et al.

Title

Reszinate—A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratrol Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling

Authors

Henry Kaplan, ProvidenceFollow
Kai Wang, ProvidenceFollow
Kimberly M. Reeves, ProvidenceFollow
James Scanlan, ProvidenceFollow
Christopher C. Nunn, ProvidenceFollow
Douglas A. Kieper, ProvidenceFollow
Joshua L. Mark, ProvidenceFollow
Inyoul Lee, ProvidenceFollow
Rachel Liu, ProvidenceFollow
Ruyun Jin, ProvidenceFollow
Michael J. Bolton, ProvidenceFollow
Jason D. Goldman, ProvidenceFollow

Document Type

Article

Publication Date

7-15-2022

Keywords

oregon; portland; swedish; isb; washington; covid-19

Department

Infectious Diseases

Comments

Front. Drug Discov., 15 July 2022 Sec. Anti-Infective Agents

Recommended Citation

Kaplan, Henry; Wang, Kai; Reeves, Kimberly M.; Scanlan, James; Nunn, Christopher C.; Kieper, Douglas A.; Mark, Joshua L.; Lee, Inyoul; Liu, Rachel; Jin, Ruyun; Bolton, Michael J.; and Goldman, Jason D., "Reszinate—A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratrol Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling" (2022). Articles, Abstracts, and Reports. 6889.
https://digitalcommons.psjhealth.org/publications/6889